Market Overview:
Renal biomarkers are proteins and molecules that are present in the kidney or urine and can indicate the presence or absence of kidney disease, kidney damage, and other conditions affecting kidney health. Common renal biomarkers include creatinine, albumin, beta-2 microglobulin, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and cystatin C. These biomarkers provide important information to doctors regarding the stage of kidney disease and its progression.

Market key trends:
The increasing prevalence of chronic kidney diseases across the globe is the major factor contributing to the growth of the renal biomarkers market. For instance, according to the National Kidney Foundation and American Kidney Fund report in 2018, around 37 million adults in the United States were estimated to have chronic kidney disease. Further, as per World Health Organization, in 2019, chronic kidney disease caused approximately 2 million deaths globally.

Moreover, research initiatives focused on developing new and more specific renal biomarkers for early detection of kidney injury is also expected to boost market growth. Additionally, growing number of clinical trials evaluating the diagnostic and prognostic utility of renal biomarkers is further propelling the market growth.

Key Takeaways

The global Renal Biomarkers Market Size is expected to witness high growth, exhibiting CAGR of 8.2% over the forecast period, due to increasing prevalence of kidney ailments like chronic kidney disease. The market size for 2023 is US$ 1,476.2 Mn.

Read More: https://newsinsights123.blogspot.com/2023/11/the-renal-biomarkers-market-is.html